Marazuela M, Vargas J A, Alvarez-Mon M, Albarrán F, Lucas T, Durántez A
Service of Endocrinology, Hospital de la Princesa, Madrid, Spain.
Eur J Endocrinol. 1995 Feb;132(2):175-80. doi: 10.1530/eje.0.1320175.
We studied the natural killer (NK) activity of peripheral blood mononuclear cells (PBMC) in patients with Graves' disease (GD). Peripheral blood mononuclear cells from 20 untreated hyperthyroid patients with GD showed a significantly reduced NK activity against 51 Cr-labeled K562 cells (33.9 +/- 15.9%), while in 32 euthyroid patients under antithyroid drug therapy. NK activity was similar to that of controls (46.9 +/- 17.3 and 49.9 +/- 20.2%, respectively). Furthermore, normalization of thyroid function with antithyroid drugs was associated with a significant increase and normalization of NK activity during the follow-up of nine GD patients (from 29.2 +/- 17.9 to 48.1 +/- 16.5%). This phenomenon could not be ascribed to a defective number of NK cells because the amounts of CD56+ and CD16+ cells in PBMC from both hyperthyroid and euthyroid GD patients were within normal ranges. Natural killer activity of PBMC from patients with toxic multinodular goiter was similar to that of normal controls (45 +/- 12.8 to 49.9 +/- 20%). No correlation was found between natural killer activity and serum levels of free thyroxine, TSH-inhibitory immunoglobulins, thyroidal antibodies to thryoglobulin and thyroidal microsomal antigen, dose or duration of antithyroid drug therapy. Natural killer activity from both controls and GD patients was enhanced in vitro by addition of recombinant interleukin 2 (IL-2), reaching control levels in hyperthyroid patients. These abnormalities were not associated with a defective IL-2 production by T cells, nor with a decreased IL-2R expression. We conclude that in untreated Graves' disease there is a decrease in NK cell activity in PBMC, probably dependent on the autoimmune process.(ABSTRACT TRUNCATED AT 250 WORDS)
我们研究了格雷夫斯病(GD)患者外周血单个核细胞(PBMC)的自然杀伤(NK)活性。20例未经治疗的甲状腺功能亢进的GD患者的外周血单个核细胞对51 Cr标记的K562细胞的NK活性显著降低(33.9±15.9%),而在32例接受抗甲状腺药物治疗的甲状腺功能正常的患者中,NK活性与对照组相似(分别为46.9±17.3%和49.9±20.2%)。此外,9例GD患者在接受抗甲状腺药物治疗使甲状腺功能恢复正常的随访过程中,NK活性显著增加并恢复正常(从29.2±17.9%升至48.1±16.5%)。这种现象不能归因于NK细胞数量的缺陷,因为甲状腺功能亢进和甲状腺功能正常的GD患者的PBMC中CD56+和CD16+细胞数量均在正常范围内。毒性多结节性甲状腺肿患者的PBMC的自然杀伤活性与正常对照组相似(45±12.8%至49.9±20%)。未发现自然杀伤活性与游离甲状腺素血清水平、TSH抑制性免疫球蛋白、甲状腺球蛋白和甲状腺微粒体抗原的甲状腺抗体、抗甲状腺药物治疗的剂量或疗程之间存在相关性。通过添加重组白细胞介素2(IL-2),对照组和GD患者的自然杀伤活性在体外均增强,甲状腺功能亢进患者达到对照水平。这些异常与T细胞产生IL-2缺陷或IL-2R表达降低无关。我们得出结论,未经治疗的格雷夫斯病患者PBMC中的NK细胞活性降低,可能依赖于自身免疫过程。(摘要截短至250字)